Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Regulating recombinant DNA biologics.

¹Department of Health and Human Services, Food and Drug Administration, Rockville, MD.

Arzneimittel-Forschung

|July 1, 1988

Summary

Biologics regulation in the US, established in 1902, has adapted to new biotechnologies like recombinant DNA. Regulatory strategies ensure the safety, purity, and efficacy of these advanced biological products.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Nucleotide sequence of a cDNA clone of Brassica napus 12S storage protein shows homology with legumin from Pisum sativum.

Plant molecular biology·2013

Same author

Development and storage-protein synthesis in Brassica napus L. embryos in vivo and in vitro.

Planta·2013

Same author

Non-zygotic embryos of Brassica napus L. contain embryo-specific storage proteins.

Planta·2013

Same author

Unusual sequence of an abscisic acid-inducible mRNA which accumulates late in Brassica napus seed development.

Plant molecular biology·2013

Same author

Precociously germinating rapeseed embryos retain characteristics of embryogeny.

Planta·2013

Same author

Binding of fibronectin by Trichomonas vaginalis is influenced by iron and calcium.

Microbial pathogenesis·2001

Area of Science:

Biotechnology
Regulatory Science
Public Health Policy

Background:

United States biologics regulation began in 1902.
The Public Health Service Act (Section 351) provides the foundational authority.
This framework has demonstrated flexibility with evolving product types.

Purpose of the Study:

To examine the regulation of new biotechnology products.
To address safety concerns arising from recombinant DNA technology.
To review current regulatory strategies for biologics.

Main Methods:

Analysis of existing regulatory frameworks.
Identification of safety issues in biotechnology products.
Review of strategies within FDA statutes and regulations.

Main Results:

The existing regulatory authority is adaptable to new biotechnologies.
Key safety concerns include molecular alterations, chemical/physical changes, and purity.
Regulatory strategies are being developed within the current legal framework.

Conclusions:

The established regulatory system effectively accommodates novel biologics.
Ongoing vigilance is necessary to address safety aspects of advanced biotechnologies.
Current strategies ensure continued safety, purity, and efficacy of regulated biologics.

Related Experiment Videos